The antiaddictive effects of ibogaine: A systematic literature review of human studies

Summary

Ibogaine, a hallucinogenic alkaloid, shows potential in reducing drug craving and withdrawal based on a systematic review of human studies. Out of 259 studies identified, eight met the criteria, with seven being open-label case series suggesting that ibogaine may significantly reduce withdrawal and craving for periods ranging from 24 hours to months. However, a randomized controlled trial of noribogaine showed no significant effects on opiate withdrawal.

Study at a glance

Abstract

Ibogaine is a naturally occurring hallucinogenic alkaloid with a therapeutic potential for reducing drug craving and withdrawal. To the best of our knowledge, no systematic review was previously performed assessing these effects. Thus, we conducted a systematic literature review of human studies assessing the antiaddictive effects of ibogaine. Papers published up to July 2, 2016 were included from PubMed, LILACS, and SciELO databases following a comprehensive search strategy and a pre-determined set of criteria for article selection. Two hundred and fifty-nine studies were identified, of which eight met the established criteria. Seven studies were open-label case series with ibogaine and one study was a randomized, placebo-controlled clinical trial with noribogaine. Case series suggest that a single dose or a few treatments with ibogaine may significantly reduce drug withdrawal, craving, and self-administration in dependent individuals lasting from 24 h to weeks or months. No significant effects of noribogaine on opiate/opioid withdrawal were observed in the clinical trial. Considering the necessity of new drugs that may produce fast-acting and sustained effects in opiate/opioid and cocaine dependence, the potential beneficial effects of ibogaine/noribogaine should be further investigated in controlled trials.

Tags